MedTrace Logo

Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

NCT03639480 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2018-08-21

No results posted yet for this study

Summary

To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia

Conditions

Interventions

DRUG

Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

DRUG

Amlodipine 10mg+Valsartan 160mg

Amlodipine 10mg+Valsartan 160mg

DRUG

Valsartan 160mg+Atorvastatin 40mg

Valsartan 160mg+Atorvastatin 40mg

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Duk-Hyun Kang, Ph.D · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639480 on ClinicalTrials.gov